USA) and subjected to qRT-PCR and cell viability assays.
Flow cytometry analysis
MM cells were treated for 3 or 6 days with 1 µM DOT1L inhibitor or with DMSO as described above, after which cells were stained with propidium iodide (Dojindo, Kumamoto, Japan) and a ApoScreen Annexin V Apoptosis Kit (Southern Biotech, Birmingham, AL, USA) according to the manufacturer's instructions. Flow cytometric analysis was then performed using a BD FACSCant II (BD Biosciences) with BD FACSDiva software (BD Biosciences). Data were analyzed using FlowJo software version 10 (FlowJo LLC, Ashland, OR, USA).
Gene expression microarray analysis
Gene expression was analyzed as described previously. 1 Briefly, 100 ng of total RNA were amplified and labeled using a Low-input Quick Amp Labeling kit One-color (Agilent Technologies, Santa Clara, CA, USA). The synthesized cRNA was hybridized to a SurePrint G3 Human GE microarray v2 (G4858A #39494; Agilent Technologies). The microarray data were imported to Gene Spring GX version 13 (Agilent Technologies). Gene ontology and pathway analyses were also performed using Gene Spring GX. The Gene Expression Omnibus accession number for the microarray data is GSE108661.
Chromatin immunoprecipitation sequencing and quantitative PCR
Chromatin immunoprecipitation (ChIP) was performed as described previously. 2 Briefly, 1 × 10 6 cells were treated for 10 min with 0.5% formaldehyde. After washing, the cells were resuspended in 110 μL of lysis buffer and sonicated. Chromatin was immunoprecipitated for 12 h at 4°C using 1 μL of rabbit anti-dimethyl histone H3K79 mAb (#5427; Cell Signaling Technology) or rabbit (DA1E) mAb IgG XP isotype control (#3900; Cell Signaling Technology) as a control. Before adding the antibody, 10 μL of each cell lysate was saved as an internal control for the input DNA.
After washing, elution, reversal of the cross-links and DNA purification, the immunoprecipitated DNA was end-repaired and ligated to Ion-compatible barcode adapters (Thermo Fisher Scientific).
Samples were then nick repaired and PCR amplified. After size selection and a quality check, samples were sequenced using an Ion Proton System (Thermo Fisher Scientific). The numbers of sequence reads in the ChIP-seq analysis are summarized in Supplementary Table 11 . Sequencing data were mapped to the human genome (UCSC hg19), and peaks were called using MACS2.0 software (GitHub, San Francisco, CA, USA) with the default broad peak setting. To identify genes whose H3K79me2 status was altered by drug treatment, we used the bdgdiff tool in MACS2.0 software (GitHub). Differential peaks with a log 10 likelihood ratio greater than 0.8 were called and were annotated using HOMER (GitHub). Peaks within intergenic regions were excluded, while those within protein coding genes were selected for further analysis. ChIP-quantitative PCR (ChIP-qPCR) was carried out using Power Up SYBR Green Master Mix (Thermo Fisher Scientific) and a 7500 Fast Real-Time PCR System (Thermo Fisher Scientific). For ChIP of DOT1L, a rabbit anti-DOT1L polyclonal antibody (A300-953A; Bethyl Laboratories, Montgomery, TX, USA) and a ChIP-IT High Sensitivity Kit (Active Motif Japan, Tokyo, Japan) were used according to manufacturer's instructions. DOT1L ChIP products were then analyzed by ChIP-qPCR or sequenced using a MiSeq system (Illumina, San Diego, CA, USA). Primer sequences and PCR product sizes are listed in Supplementary Table 10 .
Mutation analysis
Targeted sequencing of 409 cancer-related genes was performed using an Ion Ampliseq Comprehensive Cancer Panel (Thermo Fisher Scientific) and an Ion Proton System (Thermo Fisher Scientific) as described. 3 Nucleotide variants were detected using Ion Reporter (Thermo Fisher Scientific).
Statistical analysis
To analyze DOT1L expression in clinical samples, published datasets (GSE5900 and GSE6477) were obtained from the Gene Expression Omnibus. 4 
